Understanding the Basics of Dementia-Related Psychosis

Slides:

Advertisements

Similar presentations

Pharmacological Management. Only symptomatic treatment, there is no cure. Acetylcholinesterase inhibitors - Only for mild to moderate dementia –Donepezil.

Advertisements

Nuplazid™ - Pimavanserin

Expert Perspectives on New Treatment Options for Parkinson Disease Psychosis.

New Horizons for SMA.

Overview The Burden of COPD Main Challenges in the Diagnosis of COPD.

The Nurse View.

Imaging AD Progression Amyloid Imaging Agents.

How the Latest Data in MDD Can Guide Treatment Decisions:

NOACs for Cancer-Associated Thrombosis:

Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.

Making Decisions With Your Osteoarthritis Patients

The Clinical Enigma of Cardiogenic Shock

When Is Adding Aspirin to NOACs Worth the Risk?

Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.

Dry AMD and GA: The Present and Future

Emerging Data on ACS Management From ACC

Modifying Disease Course in Alzheimer's Disease

At The Cutting Edge of Developments in the Management of Hyperkalemia

From Conference to the Clinic

Progressive Fibrosing Interstitial Lung Diseases – Addressing the Challenges Concept of Progressive Fibrosing ILDs With Examples.

New Treatments for CTEPH

The Parkinson's Disease Psychosis Journal Club

Therapeutic Strategies in the Management of Mild-to-Moderate Atopic Dermatitis.

Beyond Statin Therapy.

An Update on PCSK9 Inhibitors

Updates in Neuronal Ceroid Lipofuscinosis

The future of urate-lowering strategies for gout

Antithrombotic Protection in CAD and HF

Early and Intensive T2D Management:

A Spotlight on PI3K Inhibition in Relapsed/Refractory B-Cell Lymphoma

2013 World Symposium on PH CTEPH Diagnosisa 2013 World Symposium on PH (cont) CTEPH Treatmenta.

Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors

Immunotherapy for cSCC

Best Practices in the Identification and Management of Alzheimer Agitation.

EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.

Treating CD30-Expressing Cutaneous T-Cell Lymphoma

Future Directions in Myelofibrosis: Implications of Emerging Approaches.

The Evolving Treatment Landscape in Atopic Dermatitis

Understanding and Addressing the Needs of Patients With AD

Tackling Schizophrenia With Your Patients

CAD and HF Often Coexist

The Role of the Kidney in Glucose Control

Updates in Neuronal Ceroid Lipofuscinosis

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

Are We Making Progress in the Management of Huntington Disease?

Oral Prostacyclin Pathway Agents in PAH

Add-On Therapy to Insulin in T1DM Management

On the Cusp: New Approaches for Multiple Myeloma

Introduction. Emerging Treatments for Thrombocytopenia in Adults With CLD Requiring Elective Invasive Procedures.

Background. Current Perspectives on the Management of Iron Deficiency in Chronic Heart Failure.

Assessing the Burden of Hyperkalemia

Practical Strategies for Getting Patients With Diabetes to Lipid Goal

An Update on PCSK9 Inhibitors

Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations.

Tailoring Therapy in the Newly Diagnosed Patient With CLL

Assessing the Burden of Hyperkalemia

Rational Pharmacotherapy Selection for Insomnia

Real-World Evidence.

Binge Eating Disorder.

Evaluating Success of Current Treatments for HCM

Championing Evidence-Based Care in Patients With Acute Low Back Pain

Introduction. Welcome to this program, titled De-Escalating Therapy in Epilepsy: A Return to Monotherapy.

Merging the Art and Science of Managing nOH in Clinical Practice

What's New in Oral Combination Therapy for Type 2 Diabetes?

Anemia Explored.

Treatment Advances for RA

PCSK9 Inhibitors and Real-World Evidence

Understanding the Role of Disability in MS Management

The Power of As-Treated Analyses

Translating Data From Trial to Practice

Presentation transcript:

Understanding the Basics of Dementia-Related Psychosis

Dementia

Etiological Subtype of Major and Mild NCDs

Dementia-Related Psychosis

Prevalence of Dementia and DRP in the USA

Diagnosis of DRP

Excluding Non-Dementia-Related Causes for Psychotic Symptoms

Measuring the Type, Frequency, Severity, Pattern, and Timing of Psychosis Symptoms in Clinical Practice

Neurobiology of NPS in Patients With Dementia

Neurobiology of NPS in Patients With Dementia (cont)

Potential Role of Genetics in DRP

Burden of DRP on Caregiver

AA Recommendations for the Nonpharmacologic Approach to BPSD

Rationale for Antipsychotic Therapy

Mechanism of Action of Atypical Antipsychotics

Efficacy of Antipsychotics in Patients With DRP

Safety of Antipsychotics in Patients With DRP

Rationale for SSRI Therapy in DRP

Efficacy and Safety of SSRIs

Rationale for Combining Acetylcholinesterase Inhibitors and Memantine in Treating DRP

Efficacy of AChEI + Memantine on DRP Posthoc Analysis of Pooled Data From 3 RCTs

Efficacy of AChEI + Memantine on DRP Posthoc Analysis of Pooled Data From 3 RCTs

Rational for the Use of Pimavanserin to Treat DRP

Phase 2 RDBPC Trial of the Efficacy and Safety of Pimavanserin in Patients With AD and Psychosis

Phase 2 RDBPC Trial of the Efficacy and Safety of Pimavanserin in Patients With AD Prespecified Subgroup Analysis in Patients With Severe Psychosis

Ongoing Clinical Studies for Psychosis in DPR

Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)